Business
Update on CEO Appointment
Update on CEO Appointment.
About this update from Genedrive Plc
[{"type":"text","content":"\n \nRNS Number : 5262P Epistem Holdings plc 19 February 2016 \n \n\n \n \n \nRNS Press Release\nFor release: 19 February 2016\n \nUpdate on CEO Appointment\nEpistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, is pleased to announce that, following his appointment as Chief Executive Officer and as Board Director as announced on 13 January 2016, David Budd will join Epistem on 1 March 2016.\n \nDavid has over 20 years of international commercial and operational experience in the diagnostics and medical devices field, launching multiple diagnostics products into international markets. He joins from Leica Biosystems (a Danaher company), a fast growing organisation where he served as General Manager of Leica Biosystems Amsterdam. David previously served as Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, market research and product launches for diagnostic tests.\n \nPrior to joining Leica Biosystems, David's previous roles included Point-of-Care, molecular, and central laboratory marketing and commercialization responsibilites as a Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics Inc.\n \n- Ends -\n \nFor further details please contact:\nEpistem Holdings Plc\nDr Ian Gilham: Chairman +44 (0)161 606 7258\nJohn Rylands: Finance Director\n \nPeel Hunt LLP\nJames Steel &n...